// App-Quantinova.ai

: The anti-IL-13 biologic tralokinumab did not alter expression of T2 and T17 transcription factors GATA3 and RORyT in bronchial biopsies

Researchers

Presenter

  • Latifa Chachi

Principal Investigators

  • Richard J Russell

  • Sarah Diver

  • Gillian Elliott

  • Joao P Sousa

  • Claire Emson

  • Janet Griffiths

  • Paul Newbold

  • Gene Colice

  • Christopher E Brightling

Medical Centers

  • Department of Respiratory Sciences, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, United Kingdom

  • MedImmune LLC, Gaithersburg, MD, United States of America

  • AstraZeneca Gaithersburg, Gaithersburg, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • GATA Binding Protein 3

Drug/Treatment

  • CAT-354

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT02449473

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved